JAGUAR HEALTH, INC. Deferred Offering Costs
JAGUAR HEALTH, INC. (JAGX) had Deferred Offering Costs of $13.00 thousand as of 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2022-05-10
- 2021-12-31: Deferred Offering Costs $13.00K.
- 2021-03-31: Deferred Offering Costs $88.00K.
- 2019-06-30: Deferred Offering Costs $335.77K.
- 2018-12-31: Deferred Offering Costs $1.90M.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-12-31 | $13.00K 10-K · filed 2022-03-11 |
| 2021-03-31 | $88.00K 10-Q · filed 2022-05-10 |
| 2019-06-30 | $335.77K 10-Q · filed 2019-08-14 |
| 2018-12-31 | $1.90M 10-K · filed 2019-04-10 |
| 2018-09-30 | $1.26M 10-Q · filed 2018-11-19 |
| 2017-09-30 | $303.96K 10-Q · filed 2017-11-20 |
| 2017-06-30 | $10.93K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $65.08K 10-Q/A · filed 2017-06-23 |
| 2016-12-31 | $72.71K 10-K · filed 2018-04-09 |
| 2016-09-30 | $67.01K 10-Q · filed 2016-11-14 |
| 2015-12-31 | $143.23K 10-K · filed 2017-02-15 |
| 2015-03-31 | $2.74M 10-Q · filed 2015-06-26 |
| 2014-12-31 | $2.48M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |